| Assay ID | Title | Year | Journal | Article |
|---|
| AID714014 | Inhibition of MERTK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716777 | Inhibition of SYK assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714547 | Inhibition of EGFR G719C mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716549 | Inhibition of IGF-1R assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713569 | Inhibition of PIP5K2C assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714291 | Inhibition of GSK3B assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716736 | Inhibition of EPH-A2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713536 | Inhibition of RIOK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716791 | Inhibition of PRAK assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713005 | Inhibition of EPH-B3 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714844 | Inhibition of non phosphorylated ABL1 F317L mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716522 | Inhibition of MNK2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713279 | Inhibition of SYK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714306 | Inhibition of FLT3 D835Y mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716528 | Inhibition of MKK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713007 | Inhibition of EPH-A2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714800 | Inhibition of BRSK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714060 | Inhibition of JNK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713253 | Inhibition of TYK2 JH2 pseudokinase domain assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714327 | Inhibition of ERBB3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713002 | Inhibition of ERK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714555 | Inhibition of DMPK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713797 | Inhibition of PAK6 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714557 | Inhibition of DLK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714074 | Inhibition of IKK-beta assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714598 | Inhibition of CDK11 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713788 | Inhibition of Plasmodium falciparum PFPK5 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713796 | Inhibition of PAK7 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713785 | Inhibition of PHKG1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716554 | Inhibition of HIPK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716543 | Inhibition of JAK2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712984 | Inhibition of JNK2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714860 | Half life in Swiss albino mouse brain at 1 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713016 | Inhibition of DAPK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713580 | Inhibition of PIK3CA Q546K mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713840 | Inhibition of MKK7 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713257 | Inhibition of TTK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716805 | Inhibition of PAK6 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714019 | Inhibition of MEK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715059 | Inhibition of LRRK2 in human lymphoblastoid cells assessed as inhibition of Ser910 autophosphorylation at 0.01 to 1 uM after 90 mins by immunoblot method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714053 | Inhibition of KIT V559D,T670I mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716268 | Inhibition of TBK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713539 | Inhibition of RET V804M mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713781 | Inhibition of PIK3CA assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713790 | Inhibition of PDPK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713566 | Inhibition of PKMYT1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716262 | Inhibition of TTBK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714298 | Inhibition of FYN assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716512 | Inhibition of p38a MAPK assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716264 | Inhibition of TSSK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714076 | Inhibition of IGF1R assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714824 | Inhibition of AKT1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715061 | Inhibition of GFP-tagged LRRK2 G2019S/A2016T mutant expressed in HEK293 cells assessed as inhibition of Ser910 autophosphorylation at 1 to 3 uM after 90 mins by immunoblotting method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714815 | Inhibition of ASK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714028 | Inhibition of MAPKAPK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713022 | Inhibition of CHK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716788 | Inhibition of ROCK 2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712961 | Inhibition of MST2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714012 | Inhibition of MET assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714855 | Ratio of AUClast in brain to AUClast in plasma in Swiss albino mouse at 10 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713833 | Inhibition of MRCKA assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713571 | Inhibition of PIP5K1C assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714580 | Inhibition of CLK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712968 | Inhibition of MKK6 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713269 | Inhibition of TIE2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716498 | Inhibition of PKBa assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714069 | Inhibition of IRAK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716763 | Inhibition of ABL assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714339 | Inhibition of EPHA3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714296 | Inhibition of GCN2 domain 2 S808G mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714038 | Inhibition of MAK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714556 | Inhibition of DMPK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713810 | Inhibition of NEK7 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714026 | Inhibition of MARK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714587 | Inhibition of CDKL2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713247 | Inhibition of WEE1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716508 | Inhibition of PAK2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714817 | Inhibition of ARK5 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713291 | Inhibition of SNARK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716741 | Inhibition of DDR2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714583 | Inhibition of CIT assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714043 | Inhibition of LRRK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713029 | Inhibition of BRSK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715063 | Inhibition of GFP-tagged LRRK2 A2016T mutant expressed in HEK293 cells assessed as inhibition of Ser910 autophosphorylation at 1 to 3 uM after 90 mins by immunoblotting method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714837 | Inhibition of non phosphorylated ABL1 T315I mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714829 | Inhibition of ACVR2B assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714345 | Inhibition of EGFR L861Q mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716796 | Inhibition of PKCa assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714857 | AUClast in Swiss albino mouse brain at 10 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716752 | Inhibition of CAMKKb assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713030 | Inhibition of BRK assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714822 | Inhibition of AKT3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714320 | Inhibition of ERK8 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716539 | Inhibition of Lck assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713245 | Inhibition of WEE2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714827 | Inhibition of ACVRL1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715062 | Inhibition of GFP-tagged LRRK2 A2016T mutant expressed in HEK293 cells assessed as inhibition of Ser935 autophosphorylation at 1 to 3 uM after 90 mins by immunoblotting method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716257 | Inhibition of ZAP70 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716261 | Inhibition of TTK assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714316 | Inhibition of FER assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713581 | Inhibition of PIK3CA M1043I mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714077 | Inhibition of ICK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716744 | Inhibition of CK2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713024 | Inhibition of CDK2-Cyclin A assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713258 | Inhibition of TRPM6 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716518 | Inhibition of MST3 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713829 | Inhibition of MST3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714554 | Inhibition of DRAK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714591 | Inhibition of CDK9 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716557 | Inhibition of ERK8 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713529 | Inhibition of RPS6KA4 N-terminal domain 1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714805 | Inhibition of BMPR2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716795 | Inhibition of PKCz assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714042 | Inhibition of LRRK2 G2019S mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713778 | Inhibition of PIK3CA E545A mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714859 | Volume of distribution at steady state in Swiss albino mouse brain at 1 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712974 | Inhibition of MARK4 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714823 | Inhibition of AKT2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714049 | Inhibition of LATS2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714851 | Inhibition of LRRK2 in mouse assessed as inhibition of Ser935 autophosphorylation in spleen at 100 mg/kg, ip by immunoblot method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713837 | Inhibition of MLCK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714337 | Inhibition of EPHA5 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714599 | Inhibition of CDC2L5 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714566 | Inhibition of CSNK2A2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714330 | Inhibition of EPHB4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714609 | Inhibition of CAMK2B assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714808 | Inhibition of BMPR1A assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715074 | Inhibition of GFP-tagged LRRK2 expressed in HEK293 cells assessed as inhibition of Ser935 autophosphorylation after 90 mins by immunoblotting method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714549 | Inhibition of EGFR assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716538 | Inhibition of LKB1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714828 | Inhibition of ACVR2A assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712981 | Inhibition of Lck assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713554 | Inhibition of PRKCQ assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714311 | Inhibition of FGFR4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713544 | Inhibition of QSK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716799 | Inhibition of PKA assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716514 | Inhibition of NUAK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID1489161 | Half life in Swiss albino mouse at 1 mg/kg, iv or 10 mg/kg, po | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors. |
| AID713550 | Inhibition of PRKG2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714331 | Inhibition of EPHB3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716785 | Inhibition of S6K1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714810 | Inhibition of BLK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713835 | Inhibition of MLK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716564 | Inhibition of EPH-B1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716751 | Inhibition of CDK2-Cyclin A assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715077 | Inhibition of recombinant His6-Tev-tagged LRRK2 A2016T mutant expressed in baculovirus assessed as inhibition of LRRKtide phosphorylation by HTRF assay | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716804 | Inhibition of PDK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714011 | Inhibition of MET Y1235D mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713555 | Inhibition of PRKCI assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714600 | Inhibition of CDC2L1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713533 | Inhibition of RIPK4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712986 | Inhibition of IRR assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714593 | Inhibition of CDK5 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716529 | Inhibition of MINK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714847 | Inhibition of phosphorylated ABL1 E255K mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716755 | Inhibition of BRSK2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714046 | Inhibition of LIMK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714293 | Inhibition of GRK7 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716276 | Inhibition of SmMLCK assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714348 | Inhibition of EGFR L747-T751del, Sins mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715053 | Inhibition of LRRK2 in Swiss mouse 3T3 cells assessed as inhibition of Ser910 autophosphorylation after 90 mins by immunoblot method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713538 | Inhibition of RIOK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713783 | Inhibition of PIK3C2B assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714295 | Inhibition of GRK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716266 | Inhibition of TIE2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713576 | Inhibition of PIK4CB assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715068 | Inhibition of GFP-tagged LRRK2 G2019S mutant expressed in HEK293 cells assessed as inhibition of Ser935 autophosphorylation at 1 uM after 90 mins by immunoblotting method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714063 | Inhibition of JAK3 JH1catalytic domain assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714303 | Inhibition of FLT3 N841I mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713572 | Inhibition of PIP5K1A assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID1450256 | Inhibition of LRRK2 G2019S mutant (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
| Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods. |
| AID714022 | Inhibition of MEK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714562 | Inhibition of DCAMKL1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713782 | Inhibition of PIK3C2G assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713552 | Inhibition of PRKD2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714071 | Inhibition of INSRR assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716505 | Inhibition of PAK6 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712994 | Inhibition of HIPK2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713543 | Inhibition of RAF1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714032 | Inhibition of MAP4K2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712957 | Inhibition of NEK6 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713237 | Inhibition of YSK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713023 | Inhibition of CDK9/Cyclin T1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714818 | Inhibition of ANKK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715052 | Inhibition of LRRK2 in Swiss mouse 3T3 cells assessed as inhibition of Ser935 autophosphorylation after 90 mins by immunoblot method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714045 | Inhibition of LKB1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713808 | Inhibition of NIM1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714294 | Inhibition of GRK4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712990 | Inhibition of IKKe assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714336 | Inhibition of EPHA6 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712996 | Inhibition of HER4 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713249 | Inhibition of ULK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716810 | Inhibition of p38d MAPK assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714041 | Inhibition of LTK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716775 | Inhibition of TAO1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714801 | Inhibition of BRSK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713276 | Inhibition of TAOK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714340 | Inhibition of EPHA2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714820 | Inhibition of AMPK-alpha2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713530 | Inhibition of ROCK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713577 | Inhibition of PIK3CG assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714059 | Inhibition of KIT assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716768 | Inhibition of TTK assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713021 | Inhibition of CHK2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714575 | Inhibition of CSNK1A1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713818 | Inhibition of NDR2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716531 | Inhibition of MELK assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713787 | Inhibition of PFTAIRE2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713804 | Inhibition of p38-beta assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713541 | Inhibition of RET assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714024 | Inhibition of MARK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713565 | Inhibition of PKN1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714574 | Inhibition of CSNK1A1L assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714015 | Inhibition of MELK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716800 | Inhibition of PIM3 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714826 | Inhibition of ADCK4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716552 | Inhibition of HIPK3 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714073 | Inhibition of IKK-epsilon assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713827 | Inhibition of MST4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716737 | Inhibition of EF2K assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714324 | Inhibition of ERK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714054 | Inhibition of KIT V559D mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714589 | Inhibition of CDKL1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716532 | Inhibition of MARK4 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716278 | Inhibition of SGK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713000 | Inhibition of ERK8 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713025 | Inhibition of CAMK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713265 | Inhibition of TNK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712992 | Inhibition of IGF-1R assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713803 | Inhibition of p38-gamma assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713524 | Inhibition of RSK1 N-terminal domain 1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713235 | Inhibition of ZAP70 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716765 | Inhibition of WNK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716743 | Inhibition of CSK assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716551 | Inhibition of HIPK2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714548 | Inhibition of EGFR E746-A750del mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713562 | Inhibition of PLK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713807 | Inhibition of NLK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713259 | Inhibition of TRKB assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716769 | Inhibition of TSSK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716516 | Inhibition of NEK2a assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713288 | Inhibition of SRMS assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714570 | Inhibition of CSNK1G2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714323 | Inhibition of ERK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714596 | Inhibition of CDK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713280 | Inhibition of STK36 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID1489165 | Volume of distribution at steady state in Swiss albino mouse at 1 mg/kg, iv or 10 mg/kg, po | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors. |
| AID712976 | Inhibition of MARK2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714285 | Inhibition of HIPK4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714606 | Inhibition of CAMK2G assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714568 | Inhibition of CSNK2A1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714034 | Inhibition of MAP3K3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713287 | Inhibition of SRPK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712963 | Inhibition of MPSK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716753 | Inhibition of CAMK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713011 | Inhibition of EF2K assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714854 | Inhibition of LRRK2 in mouse assessed as inhibition of Ser910 autophosphorylation in kidney at 100 mg/kg, ip by immunoblot method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716537 | Inhibition of MAPKAP-K3 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714809 | Inhibition of BIKE assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713802 | Inhibition of p38-delta assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713261 | Inhibition of TNNI3K assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716801 | Inhibition of PIM2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716760 | Inhibition of ASK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716807 | Inhibition of PAK4 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714545 | Inhibition of EGFR L747-E749del, A750P mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713801 | Inhibition of PAK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716258 | Inhibition of YES1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713821 | Inhibition of MYO3A assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714035 | Inhibition of MAP3K2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713282 | Inhibition of STK35 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713816 | Inhibition of NEK11 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714300 | Inhibition of FLT4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716497 | Inhibition of PKBb assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714803 | Inhibition of BRAF assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716545 | Inhibition of IRAK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714561 | Inhibition of DCAMKL2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714013 | Inhibition of MET M1250T mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713293 | Inhibition of SLK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714029 | Inhibition of MAP4K5 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712985 | Inhibition of JAK2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716263 | Inhibition of TrkA assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713518 | Inhibition of RSK4 N-terminal domain 1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713292 | Inhibition of SIK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716797 | Inhibition of PKBb assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714592 | Inhibition of CDK7 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713836 | Inhibition of MLK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715078 | Inhibition of recombinant His6-Tev-tagged LRRK2 G2019S mutant expressed in baculovirus assessed as inhibition of LRRKtide phosphorylation by HTRF assay | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713274 | Inhibition of TBK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713268 | Inhibition of TIE1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716565 | Inhibition of EPH-A4 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713799 | Inhibition of PAK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714341 | Inhibition of EPHA1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716766 | Inhibition of VEG-FR assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714075 | Inhibition of IKK-alpha assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714313 | Inhibition of FGFR3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712987 | Inhibition of IRAK4 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716745 | Inhibition of CLK2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713824 | Inhibition of MYLK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714051 | Inhibition of autoinhibited KIT assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714812 | Inhibition of AURKC assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713838 | Inhibition of MKNK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714056 | Inhibition of KIT D816V mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713271 | Inhibition of TGFBR1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713830 | Inhibition of MST1R assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716527 | Inhibition of MKK2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714595 | Inhibition of CDK4-cyclinD1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713285 | Inhibition of STK16 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713006 | Inhibition of EPH-B1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714328 | Inhibition of ERBB2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716793 | Inhibition of PKD1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713570 | Inhibition of PIP5K2B assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716735 | Inhibition of EIF2AK3 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713013 | Inhibition of DDR2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716256 | Oral bioavailability in Swiss albino mouse at 10 mg/kg | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716506 | Inhibition of PAK5 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716490 | Inhibition of PRK2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714312 | Inhibition of FGFR3 G697C mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714036 | Inhibition of MAP3K15 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713815 | Inhibition of NEK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714335 | Inhibition of EPHA7 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712954 | Inhibition of p38a MAPK assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716541 | Inhibition of JNK2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714865 | Plasma clearance in Swiss albino mouse at 1 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714608 | Inhibition of CAMK2A assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713238 | Inhibition of YSK4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713806 | Inhibition of OSR1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714066 | Inhibition of JAK1 JH1 catalytic domain assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714594 | Inhibition of CDK4-cyclinD3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714064 | Inhibition of JAK2 JH1 catalytic domain assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713263 | Inhibition of TNK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713574 | Inhibition of PIM2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714572 | Inhibition of CSNK1G1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716747 | Inhibition of CK1gamma2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714040 | Inhibition of LYN assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716540 | Inhibition of JNK3 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716750 | Inhibition of CDK9/Cyclin T1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716502 | Inhibition of PIM2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713283 | Inhibition of STK33 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713010 | Inhibition of DYRK3 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714563 | Inhibition of DAPK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716757 | Inhibition of BRK assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712965 | Inhibition of MNK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714033 | Inhibition of MAP3K4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713540 | Inhibition of RET V804L mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714017 | Inhibition of MEK4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716492 | Inhibition of PLK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714037 | Inhibition of MAP3K1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716770 | Inhibition of TrkA assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714825 | Inhibition of ADCK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713823 | Inhibition of MYLK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714338 | Inhibition of EPHA4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714031 | Inhibition of MAP4K3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716501 | Inhibition of PIM1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714862 | AUClast in Swiss albino mouse brain at 1 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712989 | Inhibition of IR assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID1489158 | Intrinsic clearance in human liver microsomes | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors. |
| AID713564 | Inhibition of PKN2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713820 | Inhibition of MYO3B assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716550 | Inhibition of IKKb assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713243 | Inhibition of WNK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID1489163 | Blood clearance in Swiss albino mouse at 1 mg/kg, iv or 10 mg/kg, po | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors. |
| AID713232 | Inhibition of ASK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716534 | Inhibition of MARK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713517 | Inhibition of RSK4 C-terminal domain 2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716520 | Inhibition of MSK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716562 | Inhibition of EPH-B4 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715073 | Inhibition of GFP-tagged LRRK2 G2019S mutant expressed in HEK293 cells assessed as inhibition of Ser910 autophosphorylation after 90 mins by immunoblotting method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716274 | Inhibition of Src assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716742 | Inhibition of DAPK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714586 | Inhibition of CDKL5 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714334 | Inhibition of EPHA8 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713547 | Inhibition of PRKX assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712980 | Inhibition of LKB1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713573 | Inhibition of PIM3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714346 | Inhibition of EGFR L858R,T790M mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714573 | Inhibition of CSNK1D assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713284 | Inhibition of SRPK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID1489166 | Dose normalized AUC in Swiss albino mouse at 1 mg/kg, iv | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors. |
| AID714317 | Inhibition of FES assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713009 | Inhibition of EIF2AK3 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716259 | Inhibition of VEG-FR assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714304 | Inhibition of FLT3 K663Q mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716762 | Inhibition of ZAP70 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714841 | Inhibition of phosphorylated ABL1 H396P mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714845 | Inhibition of phosphorylated ABL1 F317I mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714610 | Inhibition of CAMK1G assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714307 | Inhibition of FLT3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712975 | Inhibition of MARK3 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716749 | Inhibition of CHK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713008 | Inhibition of EPH-A4 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712979 | Inhibition of MAPKAP-K2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712967 | Inhibition of MLK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713528 | Inhibition of ROS1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714813 | Inhibition of AURKB assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716786 | Inhibition of RSK2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713017 | Inhibition of CLK2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714564 | Inhibition of DAPK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713273 | Inhibition of TEC assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713521 | Inhibition of RSK2 C-terminal domain 2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712964 | Inhibition of MNK2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715056 | Inhibition of LRRK2 G2019S/G2019S mutant in lymphoblastoid cells isolated from Parkinson disease patient assessed as inhibition of Ser935 autophosphorylation at 0.01 to 1 uM after 90 mins by immunoblot method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714835 | Inhibition of phosphorylated ABL1 Y253F mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713776 | Inhibition of PIK3CA H1047L mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716756 | Inhibition of BRSK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716525 | Inhibition of MLK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714299 | Inhibition of FRK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716811 | Inhibition of p38b MAPK assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713794 | Inhibition of PCTK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714560 | Inhibition of DCAMKL3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713839 | Inhibition of MKNK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716761 | Inhibition of AMPK assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714853 | Inhibition of LRRK2 in mouse assessed as inhibition of Ser935 autophosphorylation in kidney at 100 mg/kg, ip by immunoblot method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714061 | Inhibition of JNK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714067 | Inhibition of ITK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716500 | Inhibition of PIM3 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716789 | Inhibition of RIPK2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712960 | Inhibition of MST3 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714550 | Inhibition of DYRK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714050 | Inhibition of LATS1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715079 | Inhibition of recombinant His6-Tev-tagged LRRK2 expressed in baculovirus assessed as inhibition of LRRKtide phosphorylation by HTRF assay | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713252 | Inhibition of ULK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714025 | Inhibition of MARK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714832 | Inhibition of ABL2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715072 | Inhibition of GFP-tagged LRRK2 G2019S mutant expressed in HEK293 cells assessed as inhibition of Ser935 autophosphorylation after 90 mins by immunoblotting method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713525 | Inhibition of RPS6KA5 C-terminal domain 2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713813 | Inhibition of NEK4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714821 | Inhibition of ALK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714565 | Inhibition of DAPK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714018 | Inhibition of MEK5 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713519 | Inhibition of RSK3 C-terminal domain 2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716782 | Inhibition of SIK3 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713789 | Inhibition of Plasmodium falciparum PFCDPK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716279 | Inhibition of S6K1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712969 | Inhibition of MKK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714290 | Inhibition of HASPIN assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713003 | Inhibition of EPH-B4 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716558 | Inhibition of FGF-R1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713295 | Inhibition of SgK110 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713270 | Inhibition of TGFBR2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712970 | Inhibition of MKK2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715070 | Inhibition of GFP-tagged LRRK2 expressed in HEK293 cells assessed as inhibition of Ser935 autophosphorylation at 0.3 to 1 uM after 90 mins by immunoblotting method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713254 | Inhibition of TXK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714319 | Inhibition of ERN1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713549 | Inhibition of PRKG1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714604 | Inhibition of CAMKK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712993 | Inhibition of HIPK3 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713545 | Inhibition of PYK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713001 | Inhibition of ERK2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713267 | Inhibition of TLK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716806 | Inhibition of PAK5 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713786 | Inhibition of PFTK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714814 | Inhibition of AURKA assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714553 | Inhibition of DRAK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714601 | Inhibition of CDC2L2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713831 | Inhibition of MST1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716555 | Inhibition of GSK3b assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714070 | Inhibition of IRAK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713230 | Inhibition of Aurora B assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713255 | Inhibition of TYK2 JH1 catalytic domain assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716489 | Inhibition of RIPK2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714577 | Inhibition of CSF1R assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714603 | Inhibition of CAMKK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712971 | Inhibition of MINK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714579 | Inhibition of CLK4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712972 | Inhibition of MELK assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713290 | Inhibition of SRC assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713275 | Inhibition of TAOK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713819 | Inhibition of NDR1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712998 | Inhibition of GCK assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713791 | Inhibition of PDGFRB assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716495 | Inhibition of PKCz assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716523 | Inhibition of MNK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714559 | Inhibition of DDR1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716519 | Inhibition of MST2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713527 | Inhibition of RPS6KA4 C-terminal domain 2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714831 | Inhibition of ACVR1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713582 | Inhibition of PIK3CA I800L mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716754 | Inhibition of BTK assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716802 | Inhibition of PIM1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714850 | Inhibition of LRRK2 in mouse assessed as inhibition of Ser910 autophosphorylation in brain at 100 mg/kg, ip by immunoblot method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714811 | Inhibition of AXL assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714332 | Inhibition of EPHB2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713784 | Inhibition of PHKG2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713811 | Inhibition of NEK6 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716491 | Inhibition of PRAK assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714585 | Inhibition of CHEK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713294 | Inhibition of SIK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716503 | Inhibition of PHK assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714546 | Inhibition of EGFR G719S mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714571 | Inhibition of CSNK1E assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713531 | Inhibition of ROCK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716507 | Inhibition of PAK4 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714039 | Inhibition of LZK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714030 | Inhibition of MAP4K4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712982 | Inhibition of JNK3 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714321 | Inhibition of ERK4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713244 | Inhibition of WNK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714044 | Inhibition of LOK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713250 | Inhibition of ULK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716260 | Inhibition of WNK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714861 | Clearance in Swiss albino mouse brain at 1 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714309 | Inhibition of FLT1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716494 | Inhibition of PKCgamma assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713532 | Inhibition of RIPK5 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713522 | Inhibition of RSK2 N-terminal domain 1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713262 | Inhibition of TRKA assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID1489159 | Inhibition of LRRK2 (unknown origin) by HTRF assay | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors. |
| AID1489170 | Ratio of drug level in Swiss albino mouse brain to blood at 1 mg/kg, iv or 10 mg/kg, po | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors. |
| AID713568 | Inhibition of PKAC-alpha assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716559 | Inhibition of ERK2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716794 | Inhibition of PKCgamma assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713256 | Inhibition of TSSK1B assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716281 | Inhibition of RSK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713020 | Inhibition of CK1gamma2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714287 | Inhibition of HIPK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713793 | Inhibition of PCTK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713558 | Inhibition of PRKCD assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716780 | Inhibition of Src assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716764 | Inhibition of YES1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713809 | Inhibition of NEK9 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716272 | Inhibition of STK33 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716790 | Inhibition of PRK2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714301 | Inhibition of autoinhibited FLT3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713832 | Inhibition of MRCKB assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714819 | Inhibition of AMPK-alpha1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713248 | Inhibition of VEGFR2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714342 | Inhibition of EIF2AK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716515 | Inhibition of NEK6 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712958 | Inhibition of NEK2a assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712997 | Inhibition of GSK3b assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714333 | Inhibition of EPHB1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714315 | Inhibition of FGFR1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715076 | Inhibition of recombinant His6-Tev-tagged LRRK2 G2019S/A2016T mutant expressed in baculovirus assessed as inhibition of LRRKtide phosphorylation by HTRF assay | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716277 | Inhibition of SIK2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716809 | Inhibition of p38g MAPK assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715057 | Inhibition of LRRK2 G2019S/G2019S mutant in lymphoblastoid cells isolated from Parkinson disease patient assessed as inhibition of Ser910 autophosphorylation at 0.01 to 1 uM after 90 mins by immunoblot method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712988 | Inhibition of IRAK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714292 | Inhibition of GSK3A assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716526 | Inhibition of MKK6 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716740 | Inhibition of DYRK2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713241 | Inhibition of YANK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714310 | Inhibition of FGR assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716265 | Inhibition of TLK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712991 | Inhibition of IKKb assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716560 | Inhibition of ERK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714558 | Inhibition of DDR2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713289 | Inhibition of SNRK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716271 | Inhibition of SYK assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716739 | Inhibition of DYRK1A assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714836 | Inhibition of phosphorylated ABL1 T315I mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714613 | Inhibition of BUB1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713028 | Inhibition of BRSK2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714302 | Inhibition of FLT3 R834Q mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713233 | Inhibition of AMPK assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713234 | Inhibition of ABL assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713281 | Inhibition of STK39 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713523 | Inhibition of RSK1 C-terminal domain 2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714284 | Inhibition of HPK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID1489168 | Oral bioavailability in Swiss albino mouse at 10 mg/kg | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors. |
| AID716510 | Inhibition of p38d MAPK assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713563 | Inhibition of Mycobacterium tuberculosis PKNB assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713012 | Inhibition of DYRK2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716536 | Inhibition of MAPKAP-K2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714016 | Inhibition of MEK6 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713242 | Inhibition of YANK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714802 | Inhibition of BRK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713542 | Inhibition of RET M918T mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716772 | Inhibition of TLK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712995 | Inhibition of HIPK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713559 | Inhibition of PLK4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713825 | Inhibition of MUSK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714611 | Inhibition of CAMK1D assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716530 | Inhibition of MEKK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713286 | Inhibition of SRPK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713266 | Inhibition of TLK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716563 | Inhibition of EPH-B2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713567 | Inhibition of PKAC-beta assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713777 | Inhibition of PIK3CA E545K mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713296 | Inhibition of SGK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714852 | Inhibition of LRRK2 in mouse assessed as inhibition of Ser910 autophosphorylation in spleen at 100 mg/kg, ip by immunoblot method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714305 | Inhibition of FLT3 ITD mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714308 | Inhibition of FLT3 D835H mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712999 | Inhibition of FGF-R1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713557 | Inhibition of PRKCE assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713299 | Inhibition of S6K1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714567 | Inhibition of CTK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713535 | Inhibition of RIPK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716273 | Inhibition of SRPK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716533 | Inhibition of MARK3 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714021 | Inhibition of MAST1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713775 | Inhibition of PIK3CA H1047Y mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714799 | Inhibition of BTK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716759 | Inhibition of Aurora A assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713026 | Inhibition of CAMKKb assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713520 | Inhibition of RSK3 N-terminal domain 1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714830 | Inhibition of ACVR1B assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716544 | Inhibition of IRR assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713780 | Inhibition of PIK3CA C420R mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714072 | Inhibition of INSR assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713246 | Inhibition of VRK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716267 | Inhibition of TESK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713264 | Inhibition of TNIK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713534 | Inhibition of RIPK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713260 | Inhibition of TRKC assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716792 | Inhibition of PLK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714846 | Inhibition of non phosphorylated ABL1 F317I mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715071 | Inhibition of GFP-tagged LRRK2 expressed in HEK293 cells assessed as inhibition of Ser910 autophosphorylation at 0.3 to 1 uM after 90 mins by immunoblotting method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712983 | Inhibition of JNK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716517 | Inhibition of MST4 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712978 | Inhibition of MAPKAP-K3 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713546 | Inhibition of PRP4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716556 | Inhibition of GCK assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712973 | Inhibition of MEKK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715058 | Inhibition of LRRK2 in human lymphoblastoid cells assessed as inhibition of Ser935 autophosphorylation at 0.01 to 1 uM after 90 mins by immunoblot method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716493 | Inhibition of PKD1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716758 | Inhibition of Aurora B assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713014 | Inhibition of DYRK1A assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714048 | Inhibition of LCK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716269 | Inhibition of TAO1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714806 | Inhibition of BMX assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714858 | Ratio of AUClast in brain to AUClast in plasma in Swiss albino mouse at 1 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716546 | Inhibition of IRAK4 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713018 | Inhibition of CK1d assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714347 | Inhibition of EGFR L858R mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714329 | Inhibition of EPHB6 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714863 | Volume of distribution at steady state in Swiss albino mouse plasma at 1 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713277 | Inhibition of TAOK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716746 | Inhibition of CK1d assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713556 | Inhibition of PRKCH assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714343 | Inhibition of EGFR T790M mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712962 | Inhibition of MSK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713027 | Inhibition of BTK assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714848 | Inhibition of AAK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716771 | Inhibition of TIE2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713272 | Inhibition of TESK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713812 | Inhibition of NEK5 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713239 | Inhibition of YES assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID1489172 | Passive permeability in MDCK cells expressing human MDR1 | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors. |
| AID714834 | Inhibition of non phosphorylated ABL1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714052 | Inhibition of KIT V559D,V654A mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID1450255 | Inhibition of full length wild-type LRRK2 (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr | 2017 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11
| Discovery of LRRK2 inhibitors by using an ensemble of virtual screening methods. |
| AID716798 | Inhibition of PKBa assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713015 | Inhibition of CSK assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713834 | Inhibition of MLK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714283 | Inhibition of HUNK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716496 | Inhibition of PKCa assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714068 | Inhibition of IRAK4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714597 | Inhibition of CDK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713004 | Inhibition of EPH-B2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714856 | AUClast in Swiss albino mouse plasma at 10 mg/kg, po | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714590 | Inhibition of CDK8 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713551 | Inhibition of PRKD3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714055 | Inhibition of KIT L576P mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714286 | Inhibition of HIPK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716787 | Inhibition of RSK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714065 | Inhibition of JAK1 JH2 pseudokinase domain assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716270 | Inhibition of TAK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714551 | Inhibition of DYRK1B assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713841 | Inhibition of MINK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713560 | Inhibition of PLK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713019 | Inhibition of CK2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712966 | Inhibition of MLK3 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713822 | Inhibition of MYLK4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714552 | Inhibition of DYRK1A assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716521 | Inhibition of MPSK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716779 | Inhibition of SRPK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716542 | Inhibition of JNK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714816 | Inhibition of ASK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716748 | Inhibition of CHK2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714314 | Inhibition of FGFR2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714838 | Inhibition of phosphorylated ABL1 Q252H mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713298 | Inhibition of SBK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714344 | Inhibition of EGFR S752-I759del mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713278 | Inhibition of TAK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714864 | Half life in Swiss albino mouse plasma at 1 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714288 | Inhibition of HIPK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716553 | Inhibition of HER4 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712955 | Inhibition of OSR1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716547 | Inhibition of IKKe assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716504 | Inhibition of PDK1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713795 | Inhibition of PCTK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716511 | Inhibition of p38b MAPK assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712977 | Inhibition of MARK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714576 | Inhibition of CSK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713236 | Inhibition of ZAK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713826 | Inhibition of MTOR assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713553 | Inhibition of PRKD1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714584 | Inhibition of CHEK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714578 | Inhibition of autoinhibited CSF1R assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713240 | Inhibition of YANK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716774 | Inhibition of TBK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713817 | Inhibition of NEK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716499 | Inhibition of PKA assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713798 | Inhibition of PAK4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716280 | Inhibition of RSK2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716738 | Inhibition of DYRK3 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713548 | Inhibition of PRKR assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714843 | Inhibition of phosphorylated ABL1 F317L mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714326 | Inhibition of ERBB4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714057 | Inhibition of KIT D816H mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712956 | Inhibition of NUAK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714289 | Inhibition of HCK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714842 | Inhibition of non phosphorylated ABL1 H396P mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716275 | Inhibition of SIK3 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714840 | Inhibition of phosphorylated ABL1 M351T mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714605 | Inhibition of CAMK4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716561 | Inhibition of EPH-B3 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715075 | Inhibition of GFP-tagged LRRK2 expressed in HEK293 cells assessed as inhibition of Ser910 autophosphorylation after 90 mins by immunoblotting method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714607 | Inhibition of CAMK2D assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716783 | Inhibition of SIK2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID1489177 | Protein binding in mouse brain | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| Discovery of 5-substituent-N-arylbenzamide derivatives as potent, selective and orally bioavailable LRRK2 inhibitors. |
| AID715060 | Inhibition of GFP-tagged LRRK2 G2019S/A2016T mutant expressed in HEK293 cells assessed as inhibition of Ser935 autophosphorylation at 1 to 3 uM after 90 mins by immunoblotting method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713537 | Inhibition of RIOK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713800 | Inhibition of PAK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714839 | Inhibition of non phosphorylated ABL1 Q252H mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714588 | Inhibition of CDKL3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716509 | Inhibition of p38g MAPK assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716548 | Inhibition of IR assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715051 | AUClast in Swiss albino mouse plasma at 1 mg/kg, iv | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716808 | Inhibition of PAK2 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714325 | Inhibition of ERK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714581 | Inhibition of CLK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713828 | Inhibition of MST2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714297 | Inhibition of GAK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713805 | Inhibition of p38-alpha assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716513 | Inhibition of OSR1 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714582 | Inhibition of CLK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713814 | Inhibition of NEK3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714602 | Inhibition of CASK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714318 | Inhibition of FAK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714058 | Inhibition of KIT A829P mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713575 | Inhibition of PIM1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716488 | Inhibition of ROCK 2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714807 | Inhibition of BMPR1B assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714612 | Inhibition of CAMK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID715069 | Inhibition of GFP-tagged LRRK2 G2019S mutant expressed in HEK293 cells assessed as inhibition of Ser910 autophosphorylation at 1 uM after 90 mins by immunoblotting method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714322 | Inhibition of ERK5 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714349 | Inhibition of EGFR L747-S752del, P753S mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713297 | Inhibition of SGK assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713231 | Inhibition of Aurora A assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716784 | Inhibition of SGK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714849 | Inhibition of LRRK2 in mouse assessed as inhibition of Ser935 autophosphorylation in brain at 100 mg/kg, ip by immunoblot method | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713579 | Inhibition of PIK3CB assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716767 | Inhibition of TTBK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714023 | Inhibition of MARK4 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714047 | Inhibition of LIMK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713526 | Inhibition of RPS6KA5 N-terminal domain 1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714062 | Inhibition of JNK1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716524 | Inhibition of MLK3 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716781 | Inhibition of SmMLCK assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714804 | Inhibition of BRAF V600E mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716535 | Inhibition of MARK2 assessed as residual activity at 1 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714027 | Inhibition of MAPKAPK5 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714833 | Inhibition of phosphorylated ABL1 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716773 | Inhibition of TESK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714569 | Inhibition of CSNK1G3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713792 | Inhibition of PDGFRA assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713779 | Inhibition of PIK3CA E542K mutant assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716778 | Inhibition of STK33 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713578 | Inhibition of PIK3CD assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716803 | Inhibition of PHK assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID714020 | Inhibition of MEK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID712959 | Inhibition of MST4 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713251 | Inhibition of TYRO3 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID713561 | Inhibition of PLK2 assessed as residual activity at 10 uM relative to control | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID716776 | Inhibition of TAK1 assessed as residual activity at 10 uM | 2012 | Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17
| GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6
| A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | | | |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |